Last €0.06 EUR
Change Today 0.00 / 0.00%
Volume 0.0
As of 2:10 AM 05/22/13 All times are local (Market data is delayed by at least 15 minutes).

ibex technologies inc (IBT) Snapshot

Open
€0.06
Previous Close
€0.06
Day High
€0.06
Day Low
€0.06
52 Week High
03/20/13 - €0.12
52 Week Low
05/9/13 - €0.06
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBEX TECHNOLOGIES INC (IBT)

Related News

No related news articles were found.

ibex technologies inc (IBT) Related Businessweek News

No Related Businessweek News Found

ibex technologies inc (IBT) Details

IBEX Technologies Inc., a biopharmaceutical company, engages in the production and sale of proprietary enzymes for use as reagents in hemostasis monitoring devices. The company also provides arthritis diagnostic kits, including Collagen Type II Cleavage Assay that measures real-time collagen type II degradation; Collagen Type I and II Cleavage Assay, which measures the amount of real-time collagen of types I and II degradation; CPII Assay-Cartilage that monitors changes in the rate of synthesis of cartilage components of type II collagen indicative of osteoarthritis and rheumatoid arthritis; and Aggrecan Chondroitin Sulfate 846 Epitope Assay, which monitors changes in the rate of synthesis of cartilage components of aggrecan indicating osteoarthritis and rheumatoid arthritis. IBEX offers its arthritis diagnostic kits primarily for the pharmaceutical research. In addition, the company provides cartilage biomarker antibodies comprising Ab1320 Aggrecan NITEGE rabbit, Col M, Type IX Collagen, and C1-2C. Further, it offers heparinase II and heparinase III research reagents; chondroitinase AC that acts as a research reagent, and involved in degradation of hyaluronic acid; and chondroitinase B, a research reagent. Additionally, the company provides sample testing services. It sells its products primarily in Canada, the United States, and Europe. The company is based in Montreal, Canada.

ibex technologies inc (IBT) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: C$239.2K
Compensation as of Fiscal Year 2012.

ibex technologies inc (IBT) Key Developments

IBEX Technologies, Inc. Announces Board Changes

IBEX Technologies, Inc. announced the departure of Nancy Bisson as Director of Finance. Nancy left IBEX in order to pursue a new venture. Effective immediately, and until the appointment of a new Director of Finance, Paul Baehr, President and CEO will act as interim Director of Finance, in addition to his current duties.

IBEX Technologies, Inc. Announces Financial Results for the Second Quarter and Six Months Ended January 31, 2013

IBEX Technologies, Inc. announced financial results for the second quarter and six months ended January 31, 2013. For the quarter, sales were totaled $741,666, an increase of 25% compared to the same period year ago. Despite this increase in sales, the company recorded a net loss of $459,993 compared to a net loss of $58,566 for the same period year ago. Cash, cash equivalents, and short-term investments totaled $1,721,860 compared to $2,846,909 as of October 31, 2012. For the six months, sales were totaled $1,496,004, an increase of 11% compared the same period in 2012. This result includes one month of sales from the newly acquired BRP. Net loss was $391,323 or $0.02 per share compared to net earnings of $86,186 or $0.00 per share in the same period last year. Loss before interests, tax, depreciation & amortization was $303,995 compared to earnings before interests, tax, depreciation & amortization of $147,786 a year ago. Cash, Cash Equivalents & short-term investments were $1,721,860 compared to $2,436,587 a year ago.

IBEX Technologies, Inc. Reports Earnings Results for the First Quarter Ended October 31, 2012

IBEX Technologies, Inc. reported earnings results for the first quarter ended October 31, 2012. For the quarter, the company reported earnings before interests, tax, depreciation & amortization was $100,243, net earnings of $68,670 on revenues of $754,338 against earnings before interests, tax, depreciation & amortization was $192,152, net earnings of $144,752 or $0.01 per share on revenues of $752,464 for the same period a year ago. The decrease in net earnings is attributable to a lower inventory allocation which is the impact of goods manufactured for sale in subsequent quarters.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBT:GR €0.06 EUR 0.00

IBT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBT.
View Industry Companies
 

Industry Analysis

IBT

Industry Average

Valuation IBT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 0.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBEX TECHNOLOGIES INC, please visit www.ibex.ca. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.